Recognition, treatment, and sequelae of congenital cytomegalovirus in Australia: An observational study

Congenital CMV (cCMV) has an overall birth prevalence of 0.6-0.7%, with approximately 10-15% symptomatic during the newborn period [1,2]. Both symptomatic and asymptomatic newborns remain at risk of long-term sequelae, particularly hearing loss and developmental delay [2]. The mainstay of long-term management remains supportive hearing and developmental interventions [3], with evidence supporting a role for antiviral therapy commenced during the newborn period for infants with symptomatic cCMV [4,5].

Source: Journal of Clinical Virology - September 27, 2018 Category: Virology Authors: Adam W Bartlett, Beverley M Hall, Pamela Palasanthiran, Brendan McMullan, Antonia W Shand, William D Rawlinson Source Type: research